Clinical Trials Logo

Filter by:
NCT ID: NCT03802110 Completed - Clinical trials for Ventricular Fibrillation

Acute Feasibility Investigation of a New S-ICD Electrode

ASE
Start date: November 29, 2018
Phase: N/A
Study type: Interventional

This is an early-stage feasibility study. This study seeks to characterize the performance of the new electrode shock configuration with the S-ICD

NCT ID: NCT03800472 Completed - Healthy Clinical Trials

A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases

Start date: January 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate how safe 2 different formulations (immediate-release (IR) and modified-release (MR) tablets) of the new compound GLPG3312 are and how well they are tolerated when they are administered to healthy volunteers. Immediate-release and modified-release tablets contain the same active ingredient, but the modified-release tablet is covered with a protective layer, so it will dissolve in the intestines and not in the stomach. GLPG3312 has not been administered to humans before. Next to assessing the safety and tolerability, the purpose of this study is to investigate how food affects how quickly and to what extent GLPG3312 in a modified release formulation is absorbed and eliminated from the body. In addition, the effect of GLPG3312 on the body will be investigated by evaluating the effect of GLPG3312 on markers of the immune response.

NCT ID: NCT03800290 Completed - Healthy Clinical Trials

Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake

Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect of two weeks clenbuterol/placebo supplementation on skeletal muscle glucose disposal in healthy male volunteers.

NCT ID: NCT03793790 Completed - Chronic Pain Clinical Trials

The Role of Learning in Nocebo Hyperalgesia

Start date: September 20, 2018
Phase: N/A
Study type: Interventional

Nocebo effects are adverse effects induced by patients' expectations. Nocebo effects on pain may underlie several clinical conditions, such as chronic pain. These effects can be learned via classical conditioning mechanisms. In the lab, nocebo effects are commonly studied via conditioning with continuous reinforcement (CRF) during which 100 percent of unconditioned pain stimuli are paired to conditioned stimuli (i.e., the activation of a mock medical device). Partial reinforcement (PRF) provides a more uncertain pairing during conditioning, where less than 100 percent of unconditioned pain stimuli are paired to conditioned stimuli. This method provides a potentially more clinically relevant learning platform to study how nocebo effects on pain are induced. In this study, the efficacy of conditioning with PRF, CRF, and sham-conditioning in inducing nocebo effects on pain will be compared. Furthermore, a counterconditioning method will be compared to an extinction method for the attenuation of nocebo effects on pain. Given the relevance of nocebo effects for patients, it is important to ascertain effective & clinically relevant methods to understand how nocebo effects may be formed and attenuated. This study is conducted by Leiden University.

NCT ID: NCT03793777 Completed - Cognitive Function Clinical Trials

The Effect of Aronia Melanocarpa Extract on Cognitive Function

Start date: October 9, 2020
Phase: N/A
Study type: Interventional

There is a great interest in improving cognitive performance, including memory and attention. Improved attention is desirable for a large group of people because it is linked to improved performance . Students and professionals can benefit from improved attention and thus performance in academic and other work environments. In addition, cognitive functioning also plays an important role in sports. Various cognitive skills, including attention, reaction time and motor function, have shown that they can influence sport performance. A completely natural supplement with aronia melanocarpa extract could be a promising way to naturally improve cognitive performance.

NCT ID: NCT03792841 Completed - Prostate Cancer Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Start date: February 5, 2019
Phase: Phase 1
Study type: Interventional

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

NCT ID: NCT03792672 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Start date: February 11, 2019
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.

NCT ID: NCT03791320 Completed - Clinical trials for Coronary Artery Disease

Fast Assessment of STenosis Severity- FASTII Study

FASTII
Start date: October 15, 2018
Phase:
Study type: Observational

The Multicenter FAST (Fast Assessment of STenosis severity) study is a prospective observational multicenter study designed to evaluate the diagnostic accuracy of offline 3D-QCA based FFR, using CAAS Workstation (Pie Medical Imaging, Maastricht, the Netherlands) in identifying hemodynamically significant coronary artery disease with pressure wire-based FFR (≤0.80) as the reference standard.

NCT ID: NCT03791138 Completed - Breast Cancer Clinical Trials

The Impact of a Web-based Patient Decision Aid for Women Considering Breast Reconstruction

TANGO
Start date: August 16, 2017
Phase: N/A
Study type: Interventional

This study evaluates the impact of an online patient decision aid on the process of decision making regarding breast reconstruction and the decision quality in women with breast cancer undergoing mastectomy and considering immediate breast reconstruction. Half of participants will receive care as usual and access to the online decision aid, while the other half will receive care as usual including a standard information leaflet.

NCT ID: NCT03790709 Completed - Alzheimer Disease Clinical Trials

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

Start date: July 3, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.